Generic Semaglutide Production Begins in Canadian Facilities

Manufacturing Operations Underway

Multiple Canadian pharmaceutical companies have begun production of generic semaglutide at domestic manufacturing facilities following the January 4, 2026 patent expiry. This represents the first time generic versions of the active ingredient found in Ozempic and Wegovy are being produced within Canada's borders.

Industry sources confirm that production lines at facilities operated by Sandoz, Apotex, and Teva have initiated manufacturing processes for various semaglutide formulations. The domestic production capability positions Canada as a key supplier for both national distribution and potential export markets.

Health Canada Review Status

While manufacturing has begun, Health Canada continues reviewing nine generic semaglutide applications submitted by pharmaceutical companies. The generic semaglutide tracker indicates that approval decisions are expected throughout 2026, with initial approvals potentially coming by spring.

Current applications under review include submissions from:

• Sandoz Canada Inc.
• Apotex Inc.
• Teva Canada Limited
• Taro Pharmaceuticals Inc.
• Aspen Pharmacare Canada
• Vimy Pharma Inc.
• Three additional unnamed applicants

Production Scale and Capacity

Canadian facilities are reportedly producing multiple strengths of generic semaglutide injection solutions, including 0.25mg, 0.5mg, 1.0mg, and 2.0mg pre-filled pen formats. Manufacturing capacity is being scaled to meet anticipated demand once regulatory approvals are granted.

Pharmaceutical industry analysts note that domestic production provides supply chain advantages and potential cost efficiencies compared to imported generic alternatives. The production capability also supports Canada's pharmaceutical sovereignty initiatives.

Market Preparation Activities

While production proceeds, companies are simultaneously preparing distribution networks and pharmacy partnerships for eventual market launch. Several major pharmacy chains, including Shoppers Drug Mart, Costco, and Walmart, have confirmed they are preparing systems to accommodate generic semaglutide products once approved.

Healthcare providers are being briefed on upcoming generic alternatives, with medical associations providing guidance on potential transitions from brand-name products. The insurance coverage checker tool is being updated to reflect anticipated generic coverage policies.

Regulatory Timeline Expectations

Health Canada's review process typically requires 12-18 months for generic drug applications, though priority review status may accelerate approvals for high-demand medications. Manufacturing readiness positions approved companies for immediate market entry upon regulatory clearance.

The regulatory body has indicated it will publish approval decisions on its generic submissions tracker as they become available. Companies with approved products will be required to demonstrate bioequivalence to reference products Mounjaro and other branded alternatives.

Industry Impact Assessment

The commencement of generic production represents a significant shift in Canada's GLP-1 medication landscape. Domestic manufacturing capability reduces reliance on international suppliers and provides greater supply chain control for essential medications.

Pharmaceutical economics experts project that Canadian-produced generics could achieve cost advantages through reduced transportation and import costs. This domestic production model may influence pricing strategies for both generic and brand-name products in the Canadian market.

Additional information about generic alternatives and pricing updates is available through the FAQ section.